In October 2021, the Cancer Research UK Cambridge Centre and Abcam have announced the extension of their long-standing relationship and formalized a new framework for broad collaboration. The partners’ goal is to accelerate cancer discoveries and the translation of these discoveries into potential improvements for cancer detection, monitoring and therapies.
The ongoing collaboration combines the CRUK Cambridge Centre’s world-class cancer science with Abcam’s proteomics expertise to develop tools and solutions to help advance the understanding, diagnosis and potential treatments of cancer. The expected outcomes include knowledge sharing, collaborative development and validation of research tools, joint presentations, and the development of research products for use by cancer researchers globally.
In addition, the collaboration will leverage Abcam’s deep sector understanding and network of industrial partners to support late-stage development and accelerate the translation of future discoveries into impactful improvements for the cancer community.
The collaboration is focused in three key areas of cancer research: early detection, precision medicine and immuno-oncology.
“The CRUK Cambridge Centre is very excited by this new phase in our partnership with our neighbours Abcam on the Biomedical Campus. Most importantly, this further deepening of our relationship is great news for patients; enabling even closer working with experts at Abcam to invent new diagnostic, monitoring and treatment strategies. Combining Abcam’s innovative scientific solutions with our world-leading academic expertise will enable us to make breakthrough discoveries in our understanding of cancer.”
Richard Gilbertson
Director, Cancer Research UK Cambridge Centre
“The CRUK Cambridge Centre is very excited by this new phase in our partnership with our neighbours Abcam on the Biomedical Campus. Most importantly, this further deepening of our relationship is great news for patients; enabling even closer working with experts at Abcam to invent new diagnostic, monitoring and treatment strategies. Combining Abcam’s innovative scientific solutions with our world-leading academic expertise will enable us to make breakthrough discoveries in our understanding of cancer.”
Richard Gilbertson
Director, Cancer Research UK Cambridge Centre
“The synergy between Cancer Research UK Cambridge Centre and Abcam is catalyzed by a strong disease focus, complementary competencies and a shared mission. By ensuring rapid access to Abcam’s expertise and proteomics research tools, our goal is to help accelerate the pace of innovations that can ultimately bring potential benefits to our society.”
Alejandra Solache
SVP Research and Development, Abcam
“The synergy between Cancer Research UK Cambridge Centre and Abcam is catalyzed by a strong disease focus, complementary competencies and a shared mission. By ensuring rapid access to Abcam’s expertise and proteomics research tools, our goal is to help accelerate the pace of innovations that can ultimately bring potential benefits to our society.”
Alejandra Solache
SVP Research and Development, Abcam
“The synergy between Cancer Research UK Cambridge Centre and Abcam is catalyzed by a strong disease focus, complementary competencies and a shared mission. By ensuring rapid access to Abcam’s expertise and proteomics research tools, our goal is to help accelerate the pace of innovations that can ultimately bring potential benefits to our society.”
Alejandra Solache
SVP Research and Development, Abcam
“In recent years, cancer therapy has pivoted from a drug-centric to a patient-centric approach, highlighting the growing importance of precision medicine. Working with the scientists at the Cancer Research UK Cambridge Centre and being able to support their research efforts, we hope that we can play a small part in ultimately helping patients to get the right drug to target their cancer most effectively.”
Subham Basu
Senior Director of Strategy, Immuno-oncology and Oncology, Abcam
“In recent years, cancer therapy has pivoted from a drug-centric to a patient-centric approach, highlighting the growing importance of precision medicine. Working with the scientists at the Cancer Research UK Cambridge Centre and being able to support their research efforts, we hope that we can play a small part in ultimately helping patients to get the right drug to target their cancer most effectively.”
Subham Basu
Senior Director of Strategy, Immuno-oncology and Oncology, Abcam
The formation of the new framework has been driven by the positive progress in a number of ongoing collaborative projects between the CRUK Cambridge Centre and Abcam, and leverages the co-location of experts from both parties on the Cambridge Biomedical Campus, a European centre of innovation and excellence in healthcare.
This new relationship between the CRUK Cambridge Centre and Abcam builds on the launch of the custom partnership between Cancer Research UK and Abcam, in July 2020.
See more case studies
Registered Office:
Discovery Drive, Cambridge
Biomedical Campus,
Cambridge, CB2 0AX, UK
+44 (0) 1223 696 000
VIEW PRODUCTS
© Abcam Limited. all rights reserved.
Abcam Limited is incorporated in England and Wales, its main country of operation in the UK. Use of this website is subject to our Terms and Conditions of use and our Privacy Policy. Share price and news information on this site is updated dynamically from external data feeds.
Website by FisherPaul
